Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Inicie sesión o únase ahora para utilizar esta función

Recruiting

A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants - IM027-041

Actualizada: 06 June, 2019   |   ClinicalTrials.gov

Imprimir Resumen

¿ESTÁ CONSIDERANDO PARTICIPAR EN ESTE ESTUDIO?
Imprima esta página y la guía del estudio para poder hablar mejor con su médico.
Use la guía de estudios para explorar el proceso de participación en un estudio clínico. Comprenda qué factores clave debe considerar antes de decidirse y piense preguntas para hacerle a su equipo de atención médica.

Detalles del estudio

  • Phase 1

    Fase

  • Géneros

  • 21-65

    Rango de edad

  • 1

    Ubicación (es)

  • Recruiting

Opciones de tratamiento

Brazos del estudio
INTERVENCIÓN ASIGNADA
Experimental: BMS-986278
Drug: BMS-986278
Experimental: BMS-986278 + Pirfenidone
Drug: Pirfenidone Drug: BMS-986278
Experimental: Pirfenidone
Drug: Pirfenidone

Criterios clave de elegibilidad

Inclusion Criteria: - Signed Informed Consent. - Healthy participant, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations. Exclusion Criteria: - Women of child bearing potentia (WOCBP), pregnant or breastfeeding. - History of significant cardiovascular disease. - Participants who have smoked or used smoking cessation or nicotine containing products within 3 months of the first dose of study. Other protocol defined inclusion/exclusion criteria could apply.

¿Tiene alguna pregunta? Envíenos un correo electrónico

¿Tiene alguna pregunta?
Envíenos un correo electrónico